Grail Inc 's Cash & cash equivalent grew by 1139.84 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Grail Inc 's Quick Ratio to 10.29, above Grail Inc average Quick Ratio.

Within Medical Laboratories industry 4 other companies have achieved higher Quick Ratio than Grail Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 386, from total ranking in the first quarter 2026 at 1660.

Explain Quick Ratio?
How much Cash & cash equivalents GRAL�s has?
What are GRAL�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GRAL Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	18.27 %	-0.36 %	3.57 %	-17.86 %	-19.89 %
Y / Y Cash & cash equivalent Change	574.7 %	-48.21 %	16.57 %	-85.13 %	-86.71 %
Quick Ratio MRQ	10.29	0.93	3.13	1.64	1.8
GRAL's Total Ranking	# 386	# 1660	# 530	# 1244	# 1024
Seq. Current Liabilities Change	11.82 %	-6.23 %	2.89 %	9.62 %	-5.79 %
Seq. Cash & cash equivalent Change	1139.84 %	-72.23 %	96.8 %	-0.42 %	-4.83 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 5
Healthcare Sector	# 153
Overall Market	# 386

Quick Ratio Statistics
High	Average	Low
10.87	4.28	0.47
(Jun 30 2024)		(Dec 31 2023)

Financial Statements
Grail Inc 's Current Liabilities	$ 84 Millions	Visit GRAL's Balance sheet
Grail Inc 's Cash & cash equivalent	$ 860 Millions	Visit GRAL's Balance sheet
Source of GRAL's Sales		Visit GRAL's Sales by Geography

Cumulative Grail Inc 's Quick Ratio

GRAL's Quick Ratio for the trailling 12 Months

GRAL Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-0.46 %	-9.54 %	-35.12 %	-23.01 %	7.26 %
Y / Y Cash & cash equivalent TTM Growth	-1.76 %	-73.46 %	-69.96 %	-68.45 %	25.85 %
Quick Ratio TTM	4.14	1.9	2.11	2.01	4.2
Total Ranking TTM	# 3702	# 3874	# 2179	# 3143	# 2840
Seq. Current Liabilities TTM Growth	4.27 %	-0.09 %	0.92 %	-5.31 %	-5.25 %
Seq. Cash & cash equivalent TTM Growth	127.72 %	-10.12 %	5.89 %	-54.67 %	-38.48 %

Quick ratio ranking by company, industry and sector >> Back to GRAL Financial Strength Comparisons >> Go to Compare GRAL Quick Ratio to its Competitors

On the trailing twelve months basis GRAL Cash & cash equivalent more than doubled by 574.7 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Grail Inc 's Quick Ratio to 4.14, above GRAL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 33 other companies have achieved higher Quick Ratio than Grail Inc . While Quick Ratio overall ranking has improved so far to 3702, from total ranking during the twelve months ending first quarter 2026 at 3874.

Explain Quick Ratio?
How much Cash & cash equivalents GRAL�s has?
What are GRAL�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 34
Healthcare Sector	# 870
Within the Market	# 3702

trailing twelve months Quick Ratio Statistics
High	Average	Low
6.46	3.47	1.9
(Mar 31 2025)		(Mar 31 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Laboratories Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Aclarion Inc	15.50	$ 16.285 Millions	$ 1.051 Millions
Miragen Therapeutics Inc	12.67	$ 981.530 Millions	$ 77.484 Millions
Maxcyte inc	10.68	$ 105.690 Millions	$ 9.895 Millions
Grail Inc	10.29	$ 859.755 Millions	$ 83.542 Millions
Absci Corp	10.12	$ 201.142 Millions	$ 19.878 Millions
Billiontoone Inc	9.85	$ 548.628 Millions	$ 55.725 Millions
Celcuity Inc	8.68	$ 754.000 Millions	$ 86.873 Millions
Veracyte Inc	7.76	$ 487.046 Millions	$ 62.736 Millions
Personalis Inc	6.00	$ 278.411 Millions	$ 46.385 Millions
Castle Biosciences Inc	4.72	$ 266.805 Millions	$ 56.509 Millions
Bionexus Gene Lab Corp	4.33	$ 3.522 Millions	$ 0.813 Millions
Caredx Inc	3.99	$ 373.636 Millions	$ 93.698 Millions
Omniab Inc	3.78	$ 51.995 Millions	$ 13.758 Millions
Fulgent Genetics Inc	3.58	$ 257.032 Millions	$ 71.756 Millions
Guardant Health Inc	3.11	$ 1,053.469 Millions	$ 338.962 Millions
Butterfly Network Inc	2.13	$ 124.659 Millions	$ 58.603 Millions

Date modified: 2026-09-26T07:43:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.